Compare AbCellera Biologics Inc (ABCL) vs Vanguard Intermediate Term Corporate Bond ETF (VCIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs Vanguard Intermediate Term Corporate Bond ETF — how do they compare? AbCellera Biologics Inc trades at $9.2 (market cap $2.99B), while Vanguard Intermediate Term Corporate Bond ETF trades at $81.18. The key difference: AbCellera Biologics Inc is trading nearer its 52-week high, Vanguard Intermediate Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| ABCL | VCIT | |
|---|---|---|
Market Cap | $2.99B | — |
Sector | Health | Fixed Income |
52-Week High | $9.76 | $84.82 |
52-Week Low | $2.78 | $81.07 |
Enterprise Value | $2.58B | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Vanguard Intermediate Term Corporate Bond ETF
VCIT tracks the Bloomberg U.S. 5-10 Year Corporate Bond Index, providing exposure to investment-grade debt from industrial, utility, and financial companies. It acts as a middle-ground bond fund, offering higher yields than short-term bonds with less price volatility than long-term corporate debt.
Read more on VCIT →
